Comments
Loading...

Supernus Pharmaceuticals

SUPNNASDAQ
Logo brought to you by Benzinga Data
$31.84
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Neutral
Highest Price Target1
$36.00
Lowest Price Target1
$36.00
Consensus Price Target1
$36.00

Supernus Pharmaceuticals (NASDAQ:SUPN) Stock, Analyst Ratings, Price Targets, Forecasts

Supernus Pharmaceuticals Inc has a consensus price target of $36 based on the ratings of 1 analysts. The high is $36 issued by Piper Sandler on September 11, 2024. The low is $36 issued by Piper Sandler on September 11, 2024. The 3 most-recent analyst ratings were released by Piper Sandler on September 11, 2024, February 28, 2024, and November 9, 2023, respectively. With an average price target of $40 between Piper Sandler, there's an implied 25.63% upside for Supernus Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Supernus Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Supernus Pharmaceuticals (SUPN) stock?

A

The latest price target for Supernus Pharmaceuticals (NASDAQ:SUPN) was reported by Piper Sandler on September 11, 2024. The analyst firm set a price target for $36.00 expecting SUPN to rise to within 12 months (a possible 13.07% upside). 4 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?

A

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ:SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals downgraded their neutral rating.

Q

When was the last upgrade for Supernus Pharmaceuticals (SUPN)?

A

There is no last upgrade for Supernus Pharmaceuticals

Q

When was the last downgrade for Supernus Pharmaceuticals (SUPN)?

A

The last downgrade for Supernus Pharmaceuticals Inc happened on September 11, 2024 when Piper Sandler changed their price target from $41 to $36 for Supernus Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on September 11, 2024 so you should expect the next rating to be made available sometime around September 11, 2025.

Q

Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?

A

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a downgraded with a price target of $41.00 to $36.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $31.84, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch